Calcineurin inhibitors in renal transplantation: What is the best option?

Drugs

Volumn 63, Issue 15, 2003, Pages 1535-1548

  Tanabe, Kazunari ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ACNE; ACUTE GRAFT REJECTION; BLOOD GROUP ABO INCOMPATIBILITY; BRAIN DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DIABETOGENESIS; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG INDICATION; DRUG POTENCY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GINGIVITIS; GRAFT SURVIVAL; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERTROPHY; HYPERURICEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MICROEMULSION; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIZATION; SURVIVAL RATE; THORAX PAIN; TREMOR;

ANTI-BACTERIAL AGENTS; CALCINEURIN; CLINICAL TRIALS; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; RISK FACTORS; TACROLIMUS; TREATMENT OUTCOME;

EID: 0042122678     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363150-00002     Document Type: Review

References (60)

1. Starzl T, Klintmalm G, Weil III R, et al. Cyclosporine A and steroid therapy in sixty-six cadaver kidney recipients. Surg Gynecol Obstet 1981; 157: 309-15
2. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725-38
3. Terasaki PI, Cecka JM, Gjertson DW, et al. A ten-year prediction for kidney transplant survival. In: Terasaki PI, Cecka JM, editors. Clinical transplants 1992. Los Angeles (CA): UCLA Tissue Typing Laboratory, 1993: 501
4. Pirsch JD, Thompson D, FK506 Kidney Transplant Study Group. Tacrolimus versus cyclosporine in kidney transplantation: five-year graft survival and renal function [abstract 668]. Am J Transplant 2001; 1 Suppl. 1: 303
5. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436-43
6. Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograt) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69: 834-41
7. Ahsan N, Johnson C, Gonwa T, et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation 2001; 72: 245-50
8. Squifflet JP, Backman L, Claesson K, et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 2001; 72: 63-9
9. Margreiter R, for the European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomized multicenter study. Lancet 2002; 359: 741-6
10. Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces, I: fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987; 40: 1249-55
11. Tanaka H, Kuroda A, Marusawa H, et al. Physicochemical properties of FK-506, a novel immunosuppressant isolated from streptomyces tsukubaensis. Transplant Proc 1987 Oct; 19 Suppl. 6: 11-6
12. Spencer CM, Goa KL, Gillis JC. Tacrolimus an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997 Dec; 54 (6): 925-75
13. Peters DH, Fitton A, Plosker GL, et al. Tacrolimus: a review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993 Oct; 46: 746-94
14. De Mattos AM, Olyaei AJ, Bennet WM. Pharmacology of immunosuppressive medications used in renal diseases and transplantation. Am J Kidney Dis 1996 Nov; 28: 631-67
15. Manez R, Jain A, Marino IR, et al. Comparative evaluation of tacrolimus (FK506) and cyclosporine A as immunosuppressive agents. Transplant Rev 1995 Apr; 9 (2): 63-76
16. Morris RE. New small molecule immunosuppressants for transplantation: review of essential concepts. J Heart Lung Transplant 1993 Nov-Dec; 12: S275-86
17. Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 1995 Dec; 17: 584-91
18. Morris RE. Mechanisms of new immunosuppressive drugs. Kidney Int 1996 Jan; 49 Suppl. 53: 26-38
19. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977-83
20. Gonin JM. Maintenance immunosuppression: new agents and persistent dilemmas. Adv Ren Replace Ther 2000; 7: 95-116
21. Jensik SC, The FK506 Kidney Transplant Study Group. Tacrolimus (FK506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. Transplant Proc 1998; 30: 1216-8
22. Vincenti F, The Tacrolimus Kidney Transplant Study Group. Tacrolimus (FK506) in kidney transplantation: five-year survival results of the US multicenter, randomized, comparative trial. Transplant Proc 2001; 33: 1019-20
23. Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73: 775-82
24. Sperschneider H, for the European Renal Transplantation Study Group. A large, multicenter trial to compare the efficacy and safety of tacrolimus with cyclosporine microemulsion following renal transplantation. Transplant Proc 2001; 33: 1279-81
25. Del Castillo D, for the European Tacrolimus vs Cyclosporin-Microemulsion (CyA-ME) Renal Transplantation Study Group. Analysis of primary and recurrent rejection following renal transplantation in a large, comparative, multicenter trial. Transplant Proc 2001; 33: 1259-61
26. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60 (3): 225-32
27. Mathew TH, for the Tricontinental mycophenolate mofetil Study Group. A blinded long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation. Transplantation 1998; 65: 1450-4
28. European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3 year results from the placebo-controlled trial. Transplantation 1999; 68: 391-6
29. Tanabe K, Tokumoto T, Ishida H, et al. Excellent outcome of ABO-incompatible renal transplantation under pretransplant aggressive immunosuppression with tacrolimus, mycophenolate mofetil, and steroid. Presented at the 21st Annual Meeting of the AST; 2002 May 1; Washington, DC
30. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070-6
31. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transducfion and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335-40
32. Kahan BD, for The Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study. Lancet 2000; 356: 194-202
33. MacDonald AS, for the Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-80
34. Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation 2001; 72: 1181-93
35. Hricik DE, Anton HS, Knauss TC, et al. Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. Transplantation 2002; 74: 189-93
36. Okabe Y, Tanabe K, Tokumoto T, et al. Cyclosporine arteriolopathy (CAA) in long-term CyA treated renal allograft recipients. Presented at Transplant 2001: The Joint American Transplant Meeting; 2001 May 11-16; Chicago (IL)
37. Mihatsch MJ, Kyo M, Morozumi K, et al. The side effects of cyclosporine A and tacrolimus. Clin Nephrol 1998; 49: 356-63
38. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosposine. Transplantation 1998; 66: 1736-40
39. Johnson RWG, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777-86
40. Vanrenterghem YF. Which calcineurin inhibitor is preferred in renal transplantation: tacrolimus or cyclosporine? Curr Opin Nephrol Hypertens 1999; 8: 669-74
41. Claesson K, Mayer AD, Squifflet JP, et al. Lipoprotein patterns in renal transplant patients: a comparison between FK506 and cyclosporine A patients. Transplant Proc 1998; 30: 1292-4
42. McCune TR, Thacker II LR, Peters TG, et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation. Transplantation 1998; 65: 87-92
43. Friemann S, Feuring E, Padberg W, et al. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus. Transplant Proc 1998; 30: 1240-2
44. Manu M, Tanabe K, Tokumoto T, et al. Impact of tacrolimus on hyperlipidemia after renal transplantation: a Japanese single center experience. Transplant Proc 2000; 32: 1736-8
45. Weir MR, Fink JC. Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999; 34: 1-13
46. Jindal RM, Hjelmeseth J. Impact and management of posttransplant diabetes mellitus. Transplantation 2000; 70: S58-63
47. Neylan JF, for the FK506 Kidney Transplant Study Group. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 1998; 65: 515-23
48. Van Hooff JP, van Duijnhoven EM, Christiaans MHL. Tacrolimus and glucose metabolism. Transplant Proc 1999; 31 (7A): 49S-50S
49. Tanabe K, Tokumoto T, Ishikawa N, et al. Japanese single-center experience of kidney transplantation under tacrolimus immunosuppression. Transplant Proc 2000: 32: 1696-9
50. Perico N, Remussi G. Prevention of transplant rejection: current treatment guidelines and future developments. Drugs 1997; 54: 533-70
51. Tarantino A, Aroldi A, Stucchi L, et al. A randomized prospective trial comparing cyclosporine monotherapy with triple-drug therapy in renal transplantation. Transplantation 1991; 52: 53-7
52. Ponticelli C. Withdrawal of steroids from a cyclosporine-based regimen. Transplant Proc 1998; 30: 1782-873
53. Hricik DE, Whalen CC, Lautman J, et al. Withdrawal of steroids after renal transplantation-clinical predictors of outcome. Transplantation 1992; 53: 41-5
54. Montagnino G, Tarantino A, Segoloni GP, et al. Long-term results of a randomized study comparing three immunosuppressive schedules with cyclosporine in cadaveric kidney transplantation. J Am Soc Nephrol 2001 Oct; 12 (10): 2163-9
55. Shapiro R, Jordan ML, Scantlebuerry VP, et al. Outcome after steroid withdrawal in renal transplantation patients receiving tacrolimus-based immunosuppression. Transplant Proc 1998; 30 (4): 1375-7
56. Chakrabarti P, Wong HY, Scantleburry VP, et al. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 2000; 70: 760-4
57. Grewal HP, Thistlethwarte Jr JR, Loss GE, et al. Corticosteroid cessation 1 week following renal transplantation using tacrolimus/mycophenolate mofetil based immunosuppression. Transplant Proc 1998; 30 (4): 1378-9
58. Woodle ES. Corticosteroid withdrawal in renal transplantation. Transplant Proc 1999; 31 (1-2): 247-8
59. Mahalati K, Kahan BD. A pilot study of steroid withdrawal from kidney transplant recipients on sirolimus-cyclosporine A combination therapy. Transplant Proc 2001; 33: 3232-3
60. Swanson SJ, Hale DA, Mannon RB, et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet 2002; 360: 1662-4